Fifty-six patients with advanced HCC were randomized to two treatment groups : ( 1 ) CF-HAIC group [ n = 29 , 5-FU , 500 mg/m ( 2 ) on days 1-3 , and cisplatin , 60 mg/m ( 2 ) on day 2 ] and ( 2 ) ACF-HAIC group [ n = 27 , adriamycin , 50 mg/m ( 2 ) on day 1 , 5-FU , 500 mg/m ( 2 ) on days 1-3 , and cisplatin , 60 mg/m ( 2 ) on day 2 ] every 4 weeks via an implantable port system .